Amar Rahi
Project Director
“Joining a start-up biotech company after years of experience in Big Pharma was and is exciting – I look forward to helping progress Sutura’s drug conjugate technology aiming to have a positive impact on both patients and their families.”
Amar joined Sutura Therapeutics after 10+ years at AstraZeneca in the Early Oncology. Amar’s focus being In-vivo pharmacology - setting up, co-ordinating and monitoring pre-clinical in-vivo studies for a number of various project groups within the Early Oncology portfolio. Having a focus on In-vivo naturally lead to involvement in various 3Rs initiatives, as well as auditing CRO’s partnered with, to ensure all work was carried out to high ethical standards expected.
We believe that Amar’s experience will help contribute to the successful progression of our exciting platform.